Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/β2-microglobulin gene in patients with cancer

Human Gene Therapy

Volumn 9, Issue 14, 1998, Pages 2031-2038

  Heo, Dae Seog ^a,b   Yoon, Seong Jun ^b   Kim, Won Seog ^a   Lee, Ki Hyeong ^a   Seol, Jae Goo ^b   Lee, Sang Goo ^b   Jung, Chul Won ^a   Cho, Eun Kyung ^a   Kim, Chul Woo ^a   Park, Myoung Hee ^a   Sung, Myung Whun ^a   Kim, Kwang Hyun ^a   Bang, Yung Jue ^a   Kim, Noe Kyeong ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD4 ANTIGEN; DNA; HLA B7 ANTIGEN; MESSENGER RNA; RECOMBINANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LUNG CANCER; LYMPH NODE; LYMPHOCYTIC INFILTRATION; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; TUMOR BIOPSY;

EID: 17344364798     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.14-2031     Document Type: Article

References (15)

1. BAHLER, D., FRELINGER, J., HARWELL, L., and LORD, E.M. (1987). Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc. Natl. Acad. Sci. U.S.A. 84, 4562-4567.
2. BERKNER, K.L. (1988). Development of adenovirus vectors for the expression of heterogous genes. Biotechnique 6, 616-629.
3. CEROTTINI, J.C., and BRUNNER, K.T. (1974). Cell mediated cytotoxicity, allograft rejection and tumor immunity. Adv. Immunol. 18, 67-73.
4. COLE, G.A., CLEMENTS, V., CARCIA, E., and OSTRAND-ROSEN-BERG, S. (1987). Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 84, 8613-8617.
5. ELLIOTT, B.E., CARLOW, D.A., RODRICK, A., and WADE, A. (1989). Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53, 181-245.
6. FELGNER, P.L., and RINGOLD, G.M. (1987). Cationic liposome-mediated transfection. Nature (London) 337, 3387-3389.
7. FELGNER, P.L., GADEX, T.R., HOLM, M., ROMAN, R., CHAN, H.W., WENZ, M., NORTHROP, J.P., RINGOLD, G.M., and DANIELSEN, M. (1987). Lipofection - a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84, 7413-7418.
8. GLOAGUEN, I., COSTA, P., DEMARIS, A., LAZZARO, D., DI MARCO, A., GRAZIANI, R., PAONESSA, G., CHEN, F., ROSEN-BLUM, C.I., PLOEG, V.D., CORTESE, R., CILIBERTO, G., and LAUFER, R. (1997). Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc. Natl. Acad. Sci. U.S.A. 94, 6456-6461.
9. 2-microglobulin gene. Cancer Gene Ther. 3, S11. [Abstract O-2]
10. HUI, K.M., SIM, T., FOO, T.T., and OEI, A.A. (1989). Tumor rejection mediated by transfection with allogeneic class I major histocompatibility gene. J. Immunol. 143, 3835-3843.
11. JOLLY, D. (1994). Viral vector systems for gene therapy. Cancer Gene Ther. 1, 51-64.
12. KATZ, S.M., KIMBALL, P.M., OZAKI, C., MONSOUR, H., CLARK, J., CAVAZOS, D., KAHAN, B.D., WOOD, R.P., and KERMAN, R.H. (1994). Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation 57, 616-620.
13. LOPRINZI, C.L., LAURIE, J.A., WIEAND, H.S.. KROOK, J.E., NOVOTNY, PJ., KUGLER, J.W., BARTEL, J., LAW, M., BATEMAN, M., and KATT, N.E. (1994). Prospective evaluation of prognostic variables from patient-completed questionnaires. J. Clin. Oncol. 12, 601-607.
14. YOON, S.J., KIM, W.S., SEOL, J.G., LEE, S.G., LEE, G.H., HEO, D.S., and KIM, N.K. (1996). Preclinical study of HLA-B7 DNA/liposome complex for gene therapy. J. Korean Cancer Assoc. 28, 358-367.
15. YOON, SJ., HEO, D.S., KANG, S.H., LEE, K.H., KIM, W.S., KIM, G.P., LEE, J.A., LEE, K.S., BANG, Y.J., and KIM, N.K. (1998). Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-β1 expression. Anticancer Res. 18, 1591-1596.